Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lichochalcone A (also spelled licochalcone A) is a naturally derived chalconoid compound isolated from the roots of Glycyrrhiza species, particularly *Glycyrrhiza inflata* (Chinese licorice). It is a small molecule cosmeceutical and topical agent widely utilized for its potent antioxidant, anti-inflammatory, and photoprotective properties. Mechanistically, lichochalcone A inhibits the activation of the NLRP3 inflammasome, reduces reactive oxygen species (ROS) production, and downregulates inflammatory pathways such as NF-κB and MAPK. It is a key active ingredient in Beiersdorf's Eucerin® skincare and sunscreen formulations (such as Eucerin Sun Dry Touch Oil Control), where it is used to soothe sensitive skin, regulate sebum, and protect against UV- and high-energy visible (HEVIS) light-induced oxidative stress. In clinical studies, topical formulations containing lichochalcone A have been evaluated as effective adjuvants to retinoid therapies (like adapalene) for managing mild-to-moderate acne vulgaris and post-acne hyperpigmentation, significantly improving skin tolerability and reducing irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lichochalcone A.